Shared on 18 Sep 25
Fair value Increased 13%Analysts have raised Innate Pharma’s price target to €4.93 amid a refocused pipeline and higher risk concentration on antibody-drug conjugates, while cautioning that execution challenges, financing overhang, and lack of partnerships temper near-term confidence. Analyst Commentary Bearish analysts cite Innate Pharma's decision to deprioritize its proprietary antibody-based NK cell engager platform, which they believe overly concentrates the company’s pipeline risk onto its antibody-drug conjugate strategy.
Shared on 24 Apr 25
AnalystConsensusTarget has increased revenue growth from 5.8% to 52.7% and decreased future PE multiple from 147.8x to 49.2x.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 15%AnalystConsensusTarget has decreased revenue growth from 52.6% to 5.8%, increased profit margin from 15.6% to 17.6%, increased future PE multiple from 68.3x to 147.6x and decreased shares outstanding growth rate from 0.1% to 0.0%.